Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana Luca

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 18, 2020
Burosumab for the Treatment of Tumor-Induced OsteomalaciaSuzanne M Jan de Beur, Paul D Miller, Thomas J Weber, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 24, 2021
Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good ThingSuzanne M Jan de Beur, Paul D Miller, Thomas J Weber, et al.
Gut|June 22, 2012
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitisPaul J Rutgeerts, Richard N Fedorak, Daan W Hommes, et al.
The American Journal of Gastroenterology|October 16, 2013
EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imagingWilliam A Faubion, Joel G Fletcher, Sharon O'Byrne, et al.
Gastroenterology|November 3, 2015
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative ColitisGaik W Tew, Jason A Hackney, Deena Gibbons, et al.
Lancet (London, England)|May 13, 2014
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trialSéverine Vermeire, Sharon O'Byrne, Mary Keir, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 18, 2020
Burosumab for the Treatment of Tumor-Induced OsteomalaciaSuzanne M Jan de Beur, Paul D Miller, Thomas J Weber, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 24, 2021
Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good ThingSuzanne M Jan de Beur, Paul D Miller, Thomas J Weber, et al.
Gut|June 22, 2012
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitisPaul J Rutgeerts, Richard N Fedorak, Daan W Hommes, et al.
The American Journal of Gastroenterology|October 16, 2013
EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imagingWilliam A Faubion, Joel G Fletcher, Sharon O'Byrne, et al.
Gastroenterology|November 3, 2015
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative ColitisGaik W Tew, Jason A Hackney, Deena Gibbons, et al.
Lancet (London, England)|May 13, 2014
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trialSéverine Vermeire, Sharon O'Byrne, Mary Keir, et al.
Pageof 2